Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Akabani G, et al. Among authors: cokgor i. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58. doi: 10.1016/s0360-3016(99)00500-3. Int J Radiat Oncol Biol Phys. 2000. PMID: 10705017 Clinical Trial.
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: cokgor i. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE 2nd, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. McLendon RE, et al. Among authors: cokgor i. Nucl Med Biol. 2007 May;34(4):405-13. doi: 10.1016/j.nucmedbio.2007.01.009. Epub 2007 Mar 30. Nucl Med Biol. 2007. PMID: 17499730 Free PMC article.
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Bigner DD, et al. Among authors: cokgor i. J Clin Oncol. 1998 Jun;16(6):2202-12. doi: 10.1200/JCO.1998.16.6.2202. J Clin Oncol. 1998. PMID: 9626222 Clinical Trial.
Gliomas.
Cokgor I, Friedman AH, Friedman HS. Cokgor I, et al. Eur J Cancer. 1998 Nov;34(12):1910-5; discussion 1916-8. doi: 10.1016/s0959-8049(98)00307-4. Eur J Cancer. 1998. PMID: 10023314 Review. No abstract available.
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Cokgor I, et al. J Clin Oncol. 2000 Nov 15;18(22):3862-72. doi: 10.1200/JCO.2000.18.22.3862. J Clin Oncol. 2000. PMID: 11078500 Clinical Trial.
20 results